Tauseef Khan, MD
Cardiovascular Disease · Dubuque, IANPI 1972585610
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $15,429 of the $22,767 with a category attached, or 67.8%. 32 manufacturers reported payments, led by Abbott at 32.2% of the total. Among cardiovascular disease clinicians in IA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 345 payments — averaging $65.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$7K
- Medtronic$7K
- Terumo Medical Corporation$2K
- Bard Peripheral Vascular, Inc.$1K
- Philips North America LLC$923
- Johnson & Johnson$722
- plus $4K from 26 others
What the payments were for
- Travel & lodging$15,42968%
- Food & beverage$7,09031%
- Education$2481%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 56 | $7,337 |
| Medtronic(2 entities) | 41 | $7,312 |
| Terumo Medical Corporation | 9 | $1,608 |
| Bard Peripheral Vascular, Inc. | 18 | $1,156 |
| Philips North America LLC | 2 | $923 |
| Johnson & Johnson | 49 | $722 |
| Novartis | 32 | $591 |
| Boston Scientific | 9 | $554 |
| Merck | 13 | $236 |
| Amgen | 14 | $229 |
| Astellas Pharma US Inc | 5 | $226 |
| E.r. Squibb & Sons, L.L.C. | 14 | $222 |
| Pfizer | 14 | $220 |
| Boehringer Ingelheim | 13 | $204 |
| Shockwave Medical, Inc | 7 | $190 |
| AstraZeneca | 12 | $179 |
| Abiomed | 4 | $124 |
| Sanofi-aventis U.S. LLC | 6 | $105 |
| Esperion Therapeutics, Inc. | 4 | $92 |
| W. L. Gore & Associates, Inc. | 2 | $87 |
| Amarin Pharma, Inc. | 4 | $83 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $63 |
| Lexicon Pharmaceuticals, Inc. | 2 | $57 |
| Bayer | 2 | $42 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $38 |
| Novo Nordisk | 2 | $34 |
| Teleflex LLC | 2 | $30 |
| Bridgebio Pharma, Inc. | 1 | $26 |
| Irhythm Technologies, Inc. | 1 | $26 |
| Lantheus Medical Imaging, Inc. | 1 | $22 |
| Cardiovascular Systems Inc. | 1 | $14 |
| Regeneron Healthcare Solutions, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- IN.PACT Admiral$4,989
- Omnilink Elite vascular stent system$2,616
- XIENCE SKYPOINT$1,968
- GlideWire$1,483
- OPTIS$1,467
- Abre$1,308
- (5028) IGT Devices Systems Undivided$825
- COVERA$736
- INGEVITY$339
- Supera peripheral stent system$232
How this compares
$22,767 in reported general payments places this provider in the 90th percentile of 142 cardiovascular disease providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 782 | $843,832 |
| XareltoRivaroxaban | 290 | $353,481 |
| EntrestoSacubitril/Valsartan | 225 | $275,383 |
| JardianceEmpagliflozin | 168 | $183,401 |
| FarxigaDapagliflozin Propanediol | 153 | $140,221 |
| BrilintaTicagrelor | 117 | $79,690 |
| Repatha SureclickEvolocumab | 59 | $37,644 |
| Metoprolol Succinate | 899 | $15,895 |
| Praluent PenAlirocumab | 20 | $13,775 |
| Repatha SyringeEvolocumab | 17 | $9,045 |
| Losartan Potassium | 792 | $7,855 |
| Flecainide Acetate | 139 | $7,523 |
| Atorvastatin Calcium | 712 | $7,502 |
| ClopidogrelClopidogrel Bisulfate | 597 | $7,309 |
| Rosuvastatin Calcium | 251 | $4,313 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $220 | $843,832782 claims |
| Johnson & JohnsonXarelto | $722 | $353,481290 claims |
| NovartisEntresto | $591 | $275,383225 claims |
| AstraZenecaFarxiga, Brilinta | $179 | $219,911270 claims |
| Boehringer IngelheimJardiance | $204 | $183,401168 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 142 cardiovascular disease providers in Iowa.
Other cardiovascular disease in Dubuque
- Brian LocDubuque$6K
- Rami EltibiDubuque$5K
- Ramanujam RamabadranDubuque$4K
- Timothy MartinDubuque$4K
- Brian OlshanskyIowa City$219K
- Troy HounshellWest Des Moines$164K
- Enrico MartinWest Des Moines$113K
- Gursukhman Deep SidhuDavenport$60K
- Suzanne FeigofskyWest Des Moines$59K
- Tyler RasmussenCedar Rapids$37K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.